http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2398553-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0de3c2a3b6a654048399cc756869a0f3 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N2-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-36 |
| filingDate | 2009-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_998c921f2466bccd6da124fa80fd72af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4e5c901a12acfc9d570d2e037a7269a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bc3fd64500d64c1eaeda378bde6e1aa |
| publicationDate | 2010-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2398553-C1 |
| titleOfInvention | Method of treating optic neuropathy after craniocerebral injury in remote period |
| abstract | FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, in particular to ophthalmology. Complex treatment including introduction of emoxipin is carried out. For 10 days treatment is carried out in hospital. Additionally lidase is introduced in amount 32-64 units intramuscularly. Nootropyl is introduced intravenously in dose 5-10 ml, cerebrolysin in dose 5-10 ml. Parabulbarly introduced is dexason in dose 0.5 ml. Internally introduced is glyceroascorbate, 1 dessert spoonful, or diacarb - 1 tablet during 4 days with further interval for 3 days, or triampur compositum - 1 tablet 2 times a day. Ten sessions of electrophoresis are carried out, one per day. From negative pole introduced are enzymes from row trypsin, chymotrypsin, papain, lecozim. 3-5 sessions of hirudotherapy on region of temple, every second day, under control of coagulogramme, are carried out. The second stage of treatment is carried out in the outpatient setting during 10 days. Carried out are: intramuscular injection of proserin in dose 0.5-1.0 ml, cortexin in dose 10 mg daily, milgamma - 1.0-2.0 ml every second day. Starting with the 11-th day from beginning of treatment, 10 sessions of electric stimulation and magnetic stimulation of optic nerve are carried out. At the third stage, starting with the 21-st day, during a month carried out are: introduction of phenotropyl - 1 tablet 1 time per day, mexidol - 1 tablet 3 times a day, vinpocetine - 1 tablet 3 times a day. At the fourth stage of treatment, during a month carried out are: introduction of vasobral - 1 tablet 3 times per day, noopept - 1 tablet 2 times per day, hepabene - 1 capsule 3 times per day. Method increases optic functions in said category of patients due to carrying out complex fractional therapy. ^ EFFECT: method is simple in implementation, is endured by patients well, does not cause complications from central nervous system. ^ 2 ex, 4 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2635485-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2447864-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2578953-C1 |
| priorityDate | 2009-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 100.